Phase 2 single arm study to evaluate safety and efficacy of neoadjuvant short course radiotherapy along with chemotherapy followed by surgery in resectable carcinoma of esophagus

AIIMS Rishikesh0 sites0 target enrollmentTBD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Health Condition 1: C159- Malignant neoplasm of esophagus, unspecified
Sponsor: AIIMS Rishikesh
Status: Not yet recruiting
Last Updated: 4 years ago

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Sponsor

•1\.Histologically Proven Esophageal or Gastroesophageal junction (Sievert 1 or 2\) Carcinoma patients who are medically fit for surgery
•2\.Stage II to IVA
•3\.Age: 18\-70 years
•4\.ECOG: 0\-2
•5\.Normal hemodynamic indices before the recruitment (including white blood cell count \>4\.0Ã?109/L, neutrophil count \>1\.5Ã?109/L, platelet count \>100Ã?109/L, hemoglobin\>\=90g/l, normal liver/kidney function)
•6\.Able to understand this study and have signed informed consent.

•1\. Have been previously treated with chemotherapy, radiotherapy and other anti\-tumour treatment except surgery for non GI cancer
•2\. Known or suspected allergy to paclitaxel or carboplatin;
•3\. Female in pregnancy or lactating;
•4\. Patients with significant psychological, family, social and other factors which may affect the ability to understand and sign the informed consent;
•5\. Patients with peripheral neuropathy (CTC grade\>\=2\);
•6\. The patient not tolerant to neoadjuvant radiotherapy and chemotherapy for serious heart/lung/liver/kidney function, the haematopoietic system diseases, immune system diseases, nervous system diseases, cachexia, etc.

Not specified